935 related articles for article (PubMed ID: 27798052)
1. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation.
Bahit MC; Lopes RD; Wojdyla DM; Held C; Hanna M; Vinereanu D; Hylek EM; Verheugt F; Goto S; Alexander JH; Wallentin L; Granger CB
Heart; 2017 Apr; 103(8):623-628. PubMed ID: 27798052
[TBL] [Abstract][Full Text] [Related]
2. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
[TBL] [Abstract][Full Text] [Related]
5. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
6. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.
Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW
BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620
[TBL] [Abstract][Full Text] [Related]
7. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
[TBL] [Abstract][Full Text] [Related]
8. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
[TBL] [Abstract][Full Text] [Related]
10. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
De Caterina R; Andersson U; Alexander JH; Al-Khatib SM; Bahit MC; Goto S; Hanna M; Held C; Hohnloser S; Hylek EM; Lanas F; Lopes RD; López-Sendón J; Renda G; Horowitz J; Granger CB; Wallentin L;
Am Heart J; 2016 May; 175():175-83. PubMed ID: 27179738
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation).
Flaker G; Lopes RD; Al-Khatib SM; Hermosillo AG; Hohnloser SH; Tinga B; Zhu J; Mohan P; Garcia D; Bartunek J; Vinereanu D; Husted S; Harjola VP; Rosenqvist M; Alexander JH; Granger CB;
J Am Coll Cardiol; 2014 Mar; 63(11):1082-7. PubMed ID: 24211508
[TBL] [Abstract][Full Text] [Related]
13. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
[TBL] [Abstract][Full Text] [Related]
16. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
Trials; 2015 Sep; 16():393. PubMed ID: 26340977
[TBL] [Abstract][Full Text] [Related]
17. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
[TBL] [Abstract][Full Text] [Related]
18. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Garcia DA; Fisher DA; Mulder H; Wruck L; De Caterina R; Halvorsen S; Granger CB; Held C; Wallentin L; Alexander JH; Lopes RD
Am Heart J; 2020 Mar; 221():1-8. PubMed ID: 31896036
[TBL] [Abstract][Full Text] [Related]
19. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
[TBL] [Abstract][Full Text] [Related]
20. Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
Westenbrink BD; Alings M; Granger CB; Alexander JH; Lopes RD; Hylek EM; Thomas L; Wojdyla DM; Hanna M; Keltai M; Steg PG; De Caterina R; Wallentin L; van Gilst WH
Am Heart J; 2017 Mar; 185():140-149. PubMed ID: 28267467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
